钠-葡萄糖共转运蛋白2抑制剂减少糖尿病合并慢性乙型肝炎患者的肝事件

GastroHep Pub Date : 2021-07-02 DOI:10.1002/ygh2.471
Lilian Yan Liang, Vincent Wai-Sun Wong, Vicki Wing-Ki Hui, Terry Cheuk-Fung Yip, Yee-Kit Tse, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong
{"title":"钠-葡萄糖共转运蛋白2抑制剂减少糖尿病合并慢性乙型肝炎患者的肝事件","authors":"Lilian Yan Liang,&nbsp;Vincent Wai-Sun Wong,&nbsp;Vicki Wing-Ki Hui,&nbsp;Terry Cheuk-Fung Yip,&nbsp;Yee-Kit Tse,&nbsp;Grace Chung-Yan Lui,&nbsp;Henry Lik-Yuen Chan,&nbsp;Grace Lai-Hung Wong","doi":"10.1002/ygh2.471","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a novel class of anti-diabetic drugs that lower the blood glucose level by inhibiting the renal glucose reabsorption. We aimed to evaluate the effect of SGLT2i on the risk of hepatic events in diabetic patients with chronic hepatitis B (CHB).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This is a retrospective territory-wide cohort study. Nucleos(t)ide analogue (NA)-treated diabetic patients with CHB were included. Patients who used SGLT2i for more than 90 days were classified as SGLT2i users and those who had never used SGLT2i were defined as non-SGLT2i users. The primary endpoint was the cumulative incidence of hepatic events.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 5276 NA-treated diabetic patients with CHB, 393 (7.4%) patients were SGLT2i users and 4883 (92.6%) patients were non-users. Ten (2.5%) SGLT2i users and 739 (15.1%) non-users developed hepatic events during the mean follow-up of 25 and 63 months respectively. SGLT2i treatment was significantly associated with a lower risk of hepatic events in univariate analysis (subdistribution hazard ratio (SHR): 0.43, 95% CI: 0.22-0.84, <i>P</i> = 0.013) and log-rank test (<i>P</i> = 0.01) before propensity score (PS) weighting. This association was also observed in Fine-Gray subdistribution hazard regression after PS weighting (weighted SHR: 0.42, 95% CI: 0.19-0.90, <i>P</i> = 0.026).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Use of SGLT2i may be linked with a lower risk of hepatic events in NA-treated diabetic patients with CHB. Larger cohort studies or randomised trials are warranted.</p>\n </section>\n </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 4","pages":"261-269"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.471","citationCount":"1","resultStr":"{\"title\":\"Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B\",\"authors\":\"Lilian Yan Liang,&nbsp;Vincent Wai-Sun Wong,&nbsp;Vicki Wing-Ki Hui,&nbsp;Terry Cheuk-Fung Yip,&nbsp;Yee-Kit Tse,&nbsp;Grace Chung-Yan Lui,&nbsp;Henry Lik-Yuen Chan,&nbsp;Grace Lai-Hung Wong\",\"doi\":\"10.1002/ygh2.471\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a novel class of anti-diabetic drugs that lower the blood glucose level by inhibiting the renal glucose reabsorption. We aimed to evaluate the effect of SGLT2i on the risk of hepatic events in diabetic patients with chronic hepatitis B (CHB).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This is a retrospective territory-wide cohort study. Nucleos(t)ide analogue (NA)-treated diabetic patients with CHB were included. Patients who used SGLT2i for more than 90 days were classified as SGLT2i users and those who had never used SGLT2i were defined as non-SGLT2i users. The primary endpoint was the cumulative incidence of hepatic events.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Among 5276 NA-treated diabetic patients with CHB, 393 (7.4%) patients were SGLT2i users and 4883 (92.6%) patients were non-users. Ten (2.5%) SGLT2i users and 739 (15.1%) non-users developed hepatic events during the mean follow-up of 25 and 63 months respectively. SGLT2i treatment was significantly associated with a lower risk of hepatic events in univariate analysis (subdistribution hazard ratio (SHR): 0.43, 95% CI: 0.22-0.84, <i>P</i> = 0.013) and log-rank test (<i>P</i> = 0.01) before propensity score (PS) weighting. This association was also observed in Fine-Gray subdistribution hazard regression after PS weighting (weighted SHR: 0.42, 95% CI: 0.19-0.90, <i>P</i> = 0.026).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Use of SGLT2i may be linked with a lower risk of hepatic events in NA-treated diabetic patients with CHB. Larger cohort studies or randomised trials are warranted.</p>\\n </section>\\n </div>\",\"PeriodicalId\":12480,\"journal\":{\"name\":\"GastroHep\",\"volume\":\"3 4\",\"pages\":\"261-269\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/ygh2.471\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GastroHep\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ygh2.471\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GastroHep","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ygh2.471","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是一类新型的抗糖尿病药物,通过抑制肾脏葡萄糖重吸收来降低血糖水平。我们旨在评估SGLT2i对糖尿病合并慢性乙型肝炎(CHB)患者肝事件风险的影响。方法这是一项回顾性的区域性队列研究。核苷酸类似物(NA)治疗的糖尿病慢性乙型肝炎患者也包括在内。使用SGLT2i超过90天的患者被归类为SGLT2i使用者,从未使用过SGLT2Ⅰ的患者被定义为非SGLT2Ⅱ使用者。主要终点是肝脏事件的累计发生率。结果5276例NA治疗的糖尿病CHB患者中,393例(7.4%)为SGLT2i使用者,4883例(92.6%)为非使用者。在25个月和63个月的平均随访中,10名(2.5%)SGLT2i使用者和739名(15.1%)非使用者分别发生了肝事件。在倾向评分(PS)加权前的单变量分析(亚分布危险比(SHR)=0.43,95%CI:0.22-0.84,P=0.013)和对数秩检验(P=0.01)中,SGLT2i治疗与较低的肝事件风险显著相关。在PS加权后的Fine Gray亚分布风险回归中也观察到了这种相关性(加权SHR:0.42,95%CI:0.19-0.90,P=0.026)。结论在NA治疗的糖尿病CHB患者中,使用SGLT2i可能与较低的肝事件风险有关。有必要进行更大规模的队列研究或随机试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B

Background

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a novel class of anti-diabetic drugs that lower the blood glucose level by inhibiting the renal glucose reabsorption. We aimed to evaluate the effect of SGLT2i on the risk of hepatic events in diabetic patients with chronic hepatitis B (CHB).

Methods

This is a retrospective territory-wide cohort study. Nucleos(t)ide analogue (NA)-treated diabetic patients with CHB were included. Patients who used SGLT2i for more than 90 days were classified as SGLT2i users and those who had never used SGLT2i were defined as non-SGLT2i users. The primary endpoint was the cumulative incidence of hepatic events.

Results

Among 5276 NA-treated diabetic patients with CHB, 393 (7.4%) patients were SGLT2i users and 4883 (92.6%) patients were non-users. Ten (2.5%) SGLT2i users and 739 (15.1%) non-users developed hepatic events during the mean follow-up of 25 and 63 months respectively. SGLT2i treatment was significantly associated with a lower risk of hepatic events in univariate analysis (subdistribution hazard ratio (SHR): 0.43, 95% CI: 0.22-0.84, P = 0.013) and log-rank test (P = 0.01) before propensity score (PS) weighting. This association was also observed in Fine-Gray subdistribution hazard regression after PS weighting (weighted SHR: 0.42, 95% CI: 0.19-0.90, P = 0.026).

Conclusions

Use of SGLT2i may be linked with a lower risk of hepatic events in NA-treated diabetic patients with CHB. Larger cohort studies or randomised trials are warranted.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Hepatitis D Virus Status Among People With Hepatitis B Virus Infection: A Disconnect Between Guidelines and Practice The Use of Antibiotics for the Prophylaxis of Spontaneous Bacterial Peritonitis: A Retrospective Review and Quality Improvement Study Management of Antithrombotic Agents During Emergency Endoscopy for Upper Gastrointestinal Bleeding: A Propensity Score Matching Analysis High Technical Success Rate of Endoscopic Balloon Dilatation Reduces Surgical Requirement for Patients With Stricturing Crohn’s Disease The Suitability of Stool Antigen Testing in the Detection of Helicobacter pylori in a Regional and Rural Area of Australia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1